TEM (Tempus AI) is a US precision-medicine company that combines genetic testing, large-scale clinical data, and artificial intelligence to help diagnose and guide treatment decisions for diseases such as cancer. It provides genetic testing, data, and AI analytics to hospitals and pharmaceutical companies, and is growing rapidly but still in the red.

Revenue is generated from genetic-testing services, clinical-data licensing, and AI analytics. The company aggregates patient genetic and clinical data to support hospital treatment decisions and pharmaceutical drug development, with the value of its data assets growing as more information is collected. Test volumes, data-licensing revenue, and improvements in growth and profitability determine the business's value.

💰 How does TEM (Tempus AI) make money?

TEM (Tempus AI) generates revenue from genetic-testing services, clinical-data licensing, and AI analytics. By aggregating patient genetic and clinical data, the company helps hospitals make treatment decisions and supports pharmaceutical drug development, with the value of its data assets growing as more information is collected. Rising test volumes and growth in the data and AI business are driving rapid revenue expansion. However, the company is still loss-making, and profitability improvement, competition, and regulation/reimbursement remain key variables.

📐 TEM (Tempus AI) market cap and company size

Market cap is $14.2B and the number of 3,800 people is not publicly disclosed.

It is a US precision-medicine company that combines genetic testing with AI-powered data, providing testing and data/AI analytics to hospitals and pharmaceutical companies. Large-scale data, AI capabilities, and rapid growth are strengths, but the company is still loss-making, and profitability improvement along with competition determine its valuation.

TEM (Tempus AI) outlook and price trends

Demand for precision medicine and genetic testing, growth of the data and AI business, and expanding pharmaceutical partnerships are the medium- to long-term growth drivers. Demand for precision-medicine testing for cancer and other diseases is rising, and the accumulation of data and AI analytics is boosting data-licensing revenue and drug-development collaboration sales. The scale of data becomes a barrier to entry. However, as the company is still loss-making, profitability improvement is a challenge, and reimbursement, regulation, competition, and funding conditions are variables that heavily influence the stock price.

• Growing demand for precision medicine and genetic testing
• Growth of clinical-data and AI businesses
• Expanding pharma partnerships for drug development

⚔️ TEM (Tempus AI) core strengths and risks

Large-scale data and AI capabilities, precision-medicine demand, and rapid growth are strengths, while the loss-making position, profitability improvement, competition, and regulation/reimbursement are the key risks.

🔄 TEM (Tempus AI) competitors and related (beneficiary) stocks

TEM (Tempus AI) is directly compared with other genetic-testing companies within the precision-medicine and genetic-testing space. Liquid-biopsy player GH, genetic-testing company NTRA, and diagnostics-testing firm DGX are frequently cited as comparable names in terms of business profile and precision-medicine exposure.

✅ TEM (Tempus AI) investor checklist

TEM (Tempus AI) is a US precision-medicine company that combines genetic testing with AI-powered data. Its large-scale data assets and rapid growth are appealing, but investors must also weigh its loss-making position, profitability-improvement needs, and competitive dynamics.

Because the company is still loss-making, profitability improvement remains a challenge, and competition in the genetic-testing and precision-medicine market, changes in test reimbursement and regulation, and funding conditions can significantly affect the stock price, investors should monitor testing and data growth, profitability, and competitive dynamics together.

TEM (Tempus AI) is a US precision-medicine company with large-scale data assets, AI capabilities, precision-medicine demand, and rapid growth. However, given its loss-making position and the need for profitability improvement, along with meaningful competition and regulation/reimbursement risks, it is a stock that requires an understanding of its volatility and a cautious approach.

⚔️ TEM (Tempus AI) core strengths and risks

Large-scale data and AI capabilities, precision-medicine demand, and rapid growth are strengths, while the loss-making position, profitability improvement, competition, and regulation/reimbursement are the key risks.

🔄 TEM (Tempus AI) competitors and related (beneficiary) stocks

TEM (Tempus AI) is directly compared with other genetic-testing companies within the precision-medicine and genetic-testing space. Liquid-biopsy player GH, genetic-testing company NTRA, and diagnostics-testing firm DGX are frequently cited as comparable names in terms of business profile and precision-medicine exposure.

✅ TEM (Tempus AI) investor checklist

TEM (Tempus AI) is a US precision-medicine company that combines genetic testing with AI-powered data. Its large-scale data assets and rapid growth are appealing, but investors must also weigh its loss-making position, profitability-improvement needs, and competitive dynamics.

Because the company is still loss-making, profitability improvement remains a challenge, and competition in the genetic-testing and precision-medicine market, changes in test reimbursement and regulation, and funding conditions can significantly affect the stock price, investors should monitor testing and data growth, profitability, and competitive dynamics together.

TEM (Tempus AI) is a US precision-medicine company with large-scale data assets, AI capabilities, precision-medicine demand, and rapid growth. However, given its loss-making position and the need for profitability improvement, along with meaningful competition and regulation/reimbursement risks, it is a stock that requires an understanding of its volatility and a cautious approach.